Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 03-2025 | 12-2024 | 09-2024 | 06-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,436 | -5,196 | -29,666 | -22,876 | -15,878 |
| Depreciation Amortization | 124 | 71 | 535 | 433 | 312 |
| Accounts receivable | 3,948 | 1,948 | 2,246 | 2,538 | 263 |
| Accounts payable and accrued liabilities | 3,654 | -1,223 | -1,385 | 2,274 | 3,406 |
| Other Working Capital | -439 | -4,315 | -3,649 | -2,425 | 4,378 |
| Other Operating Activity | -4,111 | 1,804 | 16,205 | 6,212 | 4,340 |
| Operating Cash Flow | $-5,260 | $-6,911 | $-15,714 | $-13,844 | $-3,179 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -127 | -127 | N/A | N/A | N/A |
| Investing Cash Flow | $-127 | $-127 | $N/A | $N/A | $0 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 446 | 114 | 4,311 | 3,325 | 2,346 |
| Financing Cash Flow | $446 | $114 | $4,311 | $3,325 | $2,346 |
| Exchange Rate Effect | 0 | 0 | N/A | 4 | 2 |
| Beginning Cash Position | 67,234 | 67,234 | 78,637 | 78,637 | 78,637 |
| End Cash Position | 62,293 | 60,310 | 67,234 | 68,122 | 77,806 |
| Net Cash Flow | $-4,941 | $-6,924 | $-11,403 | $-10,515 | $-831 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,260 | -6,911 | -15,714 | -13,844 | -3,179 |
| Capital Expenditure | -127 | -127 | N/A | N/A | 0 |
| Free Cash Flow | -5,387 | -7,038 | -15,714 | -13,844 | -3,179 |